login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
INCYTE CORP (INCY) Stock News
USA
-
Nasdaq
- NASDAQ:INCY -
US45337C1027
-
Common Stock
96.1
USD
+0.93 (+0.98%)
Last: 12/11/2025, 8:00:02 PM
96.1
USD
0 (0%)
After Hours:
12/11/2025, 8:00:02 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
INCY Latest News, Press Relases and Analysis
All
Press Releases
3 days ago - By: Chartmill
- Mentions:
APD
TAP
LULU
RL
...
Monday's session: top gainers and losers in the S&P500 index
4 days ago - By: Chartmill
- Mentions:
APD
LULU
TPL
BSX
...
Explore the top gainers and losers within the S&P500 index in today's session.
3 days ago - By: Incyte
Incyte Presents Updated Positive Data at ASH 2025 Reinforcing the Potential of INCA033989, its First-in-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Essential Thrombocythemia
4 days ago - By: Chartmill
- Mentions:
APD
PG
LULU
BSX
...
These S&P500 stocks are gapping in today's session
4 days ago - By: Zacks Investment Research
- Mentions:
ANIP
CRMD
ARQT
Incyte's Rare Blood Cancer Therapy Gets FDA's Breakthrough Status
5 days ago - By: Incyte
Incyte Announces New Positive Data for INCA033989, its First-In-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Myelofibrosis Presented at ASH 2025
5 days ago - By: Incyte
Incyte’s First-in-Class mutCALR-Targeted Monoclonal Antibody, INCA033989, Granted Breakthrough Therapy Designation by U.S. FDA
8 days ago - By: Incyte Corporation
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
10 days ago - By: Incyte
Incyte and Winnie Harlow Join Forces to Share Her Personal Vitiligo Story and Spark Conversation and Understanding
11 days ago - By: Chartmill
- Mentions:
IRM
CCI
DELL
SNDK
...
Gapping S&P500 stocks in Monday's session
11 days ago - By: Incyte
Incyte Appoints Richard Hoffman as Executive Vice President and General Counsel
13 days ago - By: Chartmill
- Mentions:
RL
GILD
LLY
DE
...
Top S&P500 movers in Friday's session
14 days ago - By: Chartmill
- Mentions:
GILD
LLY
BBY
ORCL
...
Gapping S&P500 stocks in Friday's session
15 days ago - By: Zacks Investment Research
Incyte (INCY) Up 17.2% Since Last Earnings Report: Can It Continue?
16 days ago - By: Chartmill
INCYTE CORP (NASDAQ:INCY) Fits Minervini Trend Template with Strong Growth Momentum
22 days ago - By: Zacks Investment Research
Why Incyte (INCY) is a Top Momentum Stock for the Long-Term
23 days ago - By: Zacks Investment Research
Why Incyte (INCY) is a Top Value Stock for the Long-Term
23 days ago - By: Incyte
Incyte to Present at Upcoming Investor Conferences
24 days ago - By: The Motley Fool
- Mentions:
PTCT
TVTX
SUPN
NBIX
This Fund Sold $30 Million in PTC Therapeutics Shares Amid a 93% Rally: Here’s Why
24 days ago - By: The Motley Fool
- Mentions:
TVTX
PTCT
SUPN
NBIX
Why This Fund Trimmed a $161 Million Travere Position After a 100% Rally
a month ago - By: Benzinga
- Mentions:
PLTR
XLK
XLV
AMGN
...
Fear Of An AI Bubble? This Sector Is Quietly Surging While Tech Sinks
a month ago - By: Benzinga
Peering Into Incyte Corp's Recent Short Interest
a month ago - By: Incyte
Incyte’s Moments of Clarity Program Expands to Highlight Powerful Patient Stories in Vitiligo and Pediatric Eczema
a month ago - By: Zacks Investment Research
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
a month ago - By: Prelude Therapeutics, Incorporated
- Mentions:
PRLD
Prelude Therapeutics Announces Exclusive Option Agreement with Incyte to Advance Mutant Selective JAK2V617F JH2 Inhibitors
Please enable JavaScript to continue using this application.